Cancer Moonshot - BloodPAC


Firm Announcements and Law Updates

Getting past the bad blood of Theranos through collaboration

his week’s news that the Securities and Exchange Commission charged Theranos and its CEO with fraud put the troubles of the company back into the spotlight. For those of us in the field of liquid biopsy, Theranos has cast a long and persistent shadow on what’s clearly one of the most promising areas in cancer care — using blood tests to improve detection, diagnosis, and treatment and, more broadly, advancing the reality of precision medicine in cancer.

Read the full article:

Li Ko